Indo US Bio-Tech (NSE:INDOUS) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)

What is Indo US Bio-Tech LT-Debt-to-Total-Asset?

Indo US Bio-Tech NSE:INDOUS -2.29% 69 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates NSE:INDOUS with a GF Score™ of 69/100 and a GF Value™ of ₹312.55 (Possible Value Trap). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Indo US Bio-Tech's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

Indo US Bio-Tech's long-term debt to total assets ratio declined from Mar. 2025 (0.03) to Mar. 2026 (0.01). It may suggest that Indo US Bio-Tech is progressively becoming less dependent on debt to grow their business.

Indo US Bio-Tech (NSE:INDOUS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Indo US Bio-Tech LT-Debt-to-Total-Asset Related Terms

Indo US Bio-Tech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Indo US Bio-Tech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo US Bio-Tech LT-Debt-to-Total-Asset Chart

Indo US Bio-Tech Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.07

0.03

0.01

Indo US Bio-Tech Quarterly Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Jun22	Sep22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.00	0.01	0.00	0.01

69GF Score

Indo US Bio-Tech Ltd NSE:INDOUS

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Indo US Bio-Tech LT-Debt-to-Total-Asset Calculation

Indo US Bio-Tech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )	/	Total Assets (A: Mar. 2026 )
	=	9.519	/	1330.967
	=	0.01

Indo US Bio-Tech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	9.519	/	1330.967
	=	0.01

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.01 mean?

Indo US Bio-Tech (NSE:INDOUS) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Indo US Bio-Tech and its competitors.

Is Indo US Bio-Tech's LT-Debt-to-Total-Asset too high?

Indo US Bio-Tech's current LT-Debt-to-Total-Asset is 0.01. Overall, Indo US Bio-Tech has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Indo US Bio-Tech's LT-Debt-to-Total-Asset compare to CTVA and CF?

Indo US Bio-Tech's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for an Agriculture company?

A good LT-Debt-to-Total-Asset depends on the Agriculture industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Indo US Bio-Tech and its competitors. Indo US Bio-Tech's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Indo US Bio-Tech stock overvalued right now?

Based on GuruFocus' analysis, Indo US Bio-Tech (NSE:INDOUS) is currently considered Possible Value Trap. The stock's GF Value™ is ₹312.55, compared to a current price of ₹87.52 — trading 72% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. Indo US Bio-Tech's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Indo US Bio-Tech (NSE:INDOUS), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indo US Bio-Tech (NSE:INDOUS) Overvalued in 2026?

Based on GuruFocus' analysis, Indo US Bio-Tech stock appears to be undervalued. The current stock price of ₹87.52 is trading 72% below its estimated GF Value™ of ₹312.55. GuruFocus considers Indo US Bio-Tech to be Possible Value Trap.

Key valuation signals for NSE:INDOUS:

LT-Debt-to-Total-Asset: 0.01
GF Value™: ₹312.55 vs. price of ₹87.52 (72% below fair value)
GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the NSE:INDOUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indo US Bio-Tech Business Description

Industry Basic Materials Agriculture

Comparable Companies BOM:526081 NSE:SIKKO BOM:543643 BOM:539917 BOM:536493 NSE:NOVAAGRI NSE:BALAJIPHOS BOM:539275 BOM:543531 BOM:524687 CTVA TSX:NTR SZSE:000792 DSMD:IQCD CF SAU:2020 OSL:YAR AMM:JOPH SHSE:600096 MOS

Other Exchanges 541304:India

Address Satadhar Char Rasta, Sola Road, 309, Shanti Mall, Opposite Navrang Tower, Ahmedabad, GJ, IND, 380061

Website https://www.indousagriseeds.com

Indo US Bio-Tech Ltd is a specialized agriculture seed company. It is involved in crop research and development through breeding, production of seeds, processing, packing, and marketing of high-performing hybrid and open-pollinated varieties of crops. The company's product portfolio includes a diversified variety of agricultural seeds, namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, etc.

69GF Score

Get the complete analysis for NSE:INDOUS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹87.52

Price

₹312.55

GF Value

View NSE:INDOUS Analysis

See LT-Debt-to-Total-Asset data for all stocks →